Security key
90042W100
Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (TSBX)
CUSIP: 90042W100
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 8,434,667
- Total 13F value
- $3,026,098
- Share change
- -1,958,428
- SEC-reported price per share
- $0.36
- Number of holders
- 23
- Value change
- -$754,416
- Number of buys
- 7
- Number of sells
- 11
- Shares outstanding
- 23,142,592
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
23
Top holders
10
TSBX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Turnstone Biologics Corp. SEC filings
Turnstone Biologics Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 90042W100
Recent filing periods:
Ownership snapshot
Top reported holders of TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
13D/G
3/4/5
Lead comparable stake: 4.9%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 4.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
4.9%
ORBIMED ADVISORS LLC
13%
BML Capital Management, LLC
4.8%
PFM Health Sciences, LP
4%
TAKEDA PHARMACEUTICAL CO LTD
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
3/4/5
Company · Other*
|
4.9%
from 13D/G
|
$464,935
1,133,987 shares
|
— | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
13%
|
$1,270,699
3,099,265 shares
|
— | 31 Mar 2025 |
| BML Capital Management, LLC |
13F
Company
|
4.8%
|
$452,388
1,103,386 shares
|
— | 31 Mar 2025 |
| PFM Health Sciences, LP |
13F
Company
|
4%
|
$382,263
932,348 shares
|
— | 31 Mar 2025 |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
Company
|
3.9%
|
$367,288
895,824 shares
|
— | 31 Mar 2025 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
3.9%
|
$365,528
891,531 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
23
Shares
8,434,667
Rows available
23
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q3 2025 Across Filers
Q3 2025 holders
0
Q2 2025 holders
23
Holder diff
23
| Investor | Q3 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend